GSK (ADR)
Develops specialty medicines and vaccines through immune-system science and advanced technologies.
Something off on this page? Send us feedback.
Profile
Develops specialty medicines, vaccines, and general medicines across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. Research combines immune-system science with advanced technologies, while the business depends on clinical development, regulatory approvals, reimbursement, intellectual-property protection, and manufacturing continuity.
Develops and sells specialty medicines, vaccines, and general medicines, with research centered on immune-system science and advanced technologies. Key therapeutic areas include respiratory, immunology and inflammation, oncology, HIV, and infectious diseases, supported by products such as Nucala, Dovato, Shingrix, Arexvy, and Trelegy.
Operates from London with a workforce spread across Europe, the United States, and international markets. Long-running capabilities in respiratory medicine, vaccines, and HIV now sit within a focused biopharma portfolio after the separation of consumer health as Haleon.
Depends on successful clinical development, regulatory approvals and labels, reimbursement, intellectual-property protection, and reliable manufacturing. HIV economics and development are partly organized through ViiV Healthcare, while product availability and approved uses vary by jurisdiction.
Company facts
Key statistics
Year to date +2.4% · Average volume (30d) 3.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | HSBC | Upgrade | Reduce | Hold | |
| Jan 6, 2026 | Barclays | Downgrade | Equal Weight | Underweight | |
| Oct 30, 2025 | CFRA | Target | $53 | ||
| Nov 12, 2024 | Jefferies | Downgrade | Buy | Hold | |
| Oct 31, 2024 | Guggenheim | Downgrade | Buy | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $1.27 | $1.36 | +7.1% | $11.05B | $11.18B | +1.1% | −2.16% |
| Jul 28, 2026Q2 FY26 | $1.27 | $1.36 | +7.1% | $11.02B | $11.18B | +1.4% | −0.91% |
| Apr 29, 2026Q1 FY26 | $1.16 | $1.24 | +6.9% | $10.23B | $10.30B | +0.7% | +1.77% |
| Feb 4, 2026Q4 FY25 | $0.64 | $0.68 | +6.3% | $11.41B | $11.78B | +3.2% | +3.39% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $10.17B | $10.81B | $11.57B | $11.66B | $10.33B | $11.38B | |
| Gross profit | $7.55B | $7.88B | $8.51B | $8.07B | $7.79B | $8.31B | |
| Operating income | $3.00B | $2.74B | $3.51B | $2.04B | $3.10B | $651.1M | |
| Net income | $2.20B | $1.95B | $2.72B | $860.9M | $2.35B | $588.8M | |
| Diluted EPS | $1.06 | $0.95 | $1.33 | $0.42 | $1.16 | $0.30 | |
| Gross margin | 74.2% | 72.9% | 73.6% | 69.2% | 75.4% | 73.1% | |
| Operating margin | 29.5% | 25.3% | 30.3% | 17.5% | 30.1% | 5.7% |
Fiscal years (4-quarter sums)FY21 $39.81B · FY22 $39.69B · FY23 $41.05B · FY24 $42.47B · FY25 $44.22B
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $4.18B · Total debt $24.54B · Total assets $83.06B · Shareholders' equity $23.74B
Dividends
Raised for 2 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 14, 2026 | Aug 14 | Oct 8 | $0.4515 | cut from $0.455 |
| May 15, 2026 | May 15 | Jul 9 | $0.455 | cut from $0.4776 |
| Feb 20, 2026 | Feb 20 | Apr 9 | $0.4776 | raised from $0.4331 |
| Nov 14, 2025 | Nov 14 | Jan 8 | $0.4331 | raised from $0.43 |
| Aug 15, 2025 | Aug 15 | Oct 9 | $0.43 | cut from $0.4348 |
| May 16, 2025 | May 16 | Jul 10 | $0.4348 | raised from $0.4076 |
| Feb 21, 2025 | Feb 21 | Apr 10 | $0.4076 | raised from $0.3891 split-adjusted |
| Nov 15, 2024 | Nov 15 | Jan 9 | $0.3769 | raised from $0.3857 split-adjusted |
Ownership
Shares outstanding 2.00B · Float 1.94B · 96.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 64.96M | 3.24% | 13F | Aug 13, 2026 |
| Dodge & Cox | 48.20M | 2.41% | 13F | Aug 13, 2026 |
| Fisher Asset Management, LLC | 35.72M | 1.78% | 13F | Aug 4, 2026 |
| Primecap Management Co/CA/ | 25.18M | 1.26% | 13F | Aug 14, 2026 |
| Wellington Management Group LLP | 11.40M | 0.57% | 13F | Aug 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- AstraZeneca (ADR)
Broad respiratory rival with targeted oncology and vaccine overlap
- Pfizer
Global biopharma rival across vaccines and oncology
- Sanofi (ADR)
Broad overlap in respiratory biologics, vaccines and multiple myeloma
- Merck
Major competitor across vaccines, oncology and HIV treatment
- Gilead Sciences
Competes across HIV treatment, HIV prevention and oncology
- Bristol-Myers Squibb
Global biopharma focused on oncology, hematology and immunology
- Novartis (ADR)
Competes in respiratory biologics and myelofibrosis therapies
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GSK (ADR) | $50.57 | −0.51% | $101.82B | 15.8 | 9.2 | 2.2 | +2.7% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Median | 30.7 | 15.6 | 4.1 | +5.7% |